• Six clinical trials on MSCs approved by US FDA
    Six clinical trials on MSCs approved by US FDA
  • One of the few companies manufacturing both hMSC and hNSC
    One of the few companies manufacturing both hMSC and hNSC
  • First FDA-approved clinical trial using stem cells to treat Alzheimer’s
    First FDA-approved clinical trial using stem cells to treat Alzheimer’s
  • MSCs approved as a treatment of AMI in Kazakhstan
    MSCs approved as a treatment of AMI in Kazakhstan
  • Producing clinical-grade stem cells with strong activity in large scale
    Producing clinical-grade stem cells with strong activity in large scale
  • SCF activity preserved through patented technology for 3 years
    SCF activity preserved through patented technology for 3 years

Add:21st Floor, Block 1, Jusha Center, No.16 Xinyuanli, Chaoyang District, Beijing

Phone: 86-10-64654791

 

 

Copyright ©Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.! 

京ICP备19006400号-1     Powered by 300.cn


News Center

Press Conference of Jiuzhitang Qihang Fund’s Investment in Stemdica Cell Technologies, Inc.

Press Conference of Jiuzhitang Qihang Fund’s Investment in Stemdica Cell Technologies, Inc.

Release time:
2018-09-14 13:40
On 14 September 2018, Press Conference - Jiuzhitang Qihang Fund’s Investment in Stemdica Cell Technologies, Inc. & Global Stem Cell Industry Development Summit was held in Beijing.
Author:
Source:
Jiuzhitang Maker was officially awarded Certificate of Zhongguancun High Technology Enterprise.

Jiuzhitang Maker was officially awarded Certificate of Zhongguancun High Technology Enterprise.

Release time:
2019-02-25 17:19
Approved by the Administration Committee of Zhongguancun Science & Technology Park, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. ...
Author:
Source:
Jiuzhitang Maker signed the Cooperation Agreement on Jointly Building Jiuzhitang-ALTACO International Medical center for Stem Cells with Kazakhstan-based LLP "ALTACO-XXI" in the China-Kazakhstan Horgos Frontier International Cooperation Center.

Jiuzhitang Maker signed the Cooperation Agreement on Jointly Building Jiuzhitang-ALTACO International Medical center for Stem Cells with Kazakhstan-based LLP "ALTACO-XXI" in the China-Kazakhstan Horgos Frontier International Cooperation Center.

Release time:
2019-01-23 02:15
Jiuzhitang Maker signed the Cooperation Agreement on Jointly Building Jiuzhitang-ALTACO International Medical center for Stem Cells with ...
Author:
Source:
New Progress Achieved in Jiuzhitang M&A Fund’s Investment in Stem Cell Business

New Progress Achieved in Jiuzhitang M&A Fund’s Investment in Stem Cell Business

Release time:
2019-01-16 17:16
On January 12, 2019, Jiuzhitang Co., Ltd. made an announcement on latest progress its M&A fund achieved in investment efforts. ...
Author:
Source:
Reprinted from healthoo by Financial News
New Progress Achieved in Jiuzhitang M&A Fund’s Investment in Stem Cell Business

New Progress Achieved in Jiuzhitang M&A Fund’s Investment in Stem Cell Business

Release time:
2019-01-14 17:14
On January 12, 2019, Jiuzhitang Co., Ltd. made an announcement on latest progress its M&A fund achieved in investment efforts. ...
Author:
Source:
Healthoo
New Progress Achieved in Jiuzhitang M&A Fund’s Investment in Stem Cell Business

New Progress Achieved in Jiuzhitang M&A Fund’s Investment in Stem Cell Business

Release time:
2019-01-12 16:30
On January 12, 2019, Jiuzhitang Co., Ltd. made an announcement on latest progress its M&A fund achieved in investment efforts. ...
Author:
Source:
Jiuzhitang Maker selected as one of the Ten Key companies received “Comprehensive Service Package” offered by Daxing District

Jiuzhitang Maker selected as one of the Ten Key companies received “Comprehensive Service Package” offered by Daxing District

Release time:
2018-11-05 15:55
Daxing District Development and Reform Commission and Daxing Biomedicine Industry Base delivered “Comprehensive Service Package”...
Author:
Source:
Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction

Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction

Release time:
2018-09-12 15:34
On 12 September 2018, Stemedica completed its Phase III clinical trial of using mesenchymal stem cells to treat acute myocardial infarction ...
Author:
Source:
Jiuzhitang Maker signed cooperation agreements with Novastem from Mexico and ALTACO from Kazakhstan

Jiuzhitang Maker signed cooperation agreements with Novastem from Mexico and ALTACO from Kazakhstan

Release time:
2018-09-29 15:37
In September 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. signed cooperation agreements with Mexican company Novastem ...
Author:
Source:
Jiuzhitang Maker signed the Agreement on Co-construction of Stem Cells Clinical Research Base with Beijing Tiantan Hospital.

Jiuzhitang Maker signed the Agreement on Co-construction of Stem Cells Clinical Research Base with Beijing Tiantan Hospital.

Release time:
2018-09-14 16:32
In August 2018, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. signed Agreement on Co-construction of Stem Cell Clinical Research Base ...
Author:
Source: